lactobacillus rhamnosus Sachets

The company, founded in 1992, has a strong foundation in pharmaceutical production and regulatory affairs, initially supporting third-party companies in the registration of generic medicines in Italy. Over time, this CTD dossier owner and manufacturer developed a focus on probiotic-based products, recognizing the therapeutic potential of probiotic lactic bacteria and their derivatives as safe, low-impact alternatives for health and well-being. In 2000, it launched the first medicine based on probiotic strains for women's health, leading to a broader range of biotherapeutic products. The company has its own research and development facilities and a GMP-certified production plant, reflecting its commitment to innovation, quality, and reliability in therapeutic solutions.